Antibe Financial Statements From 2010 to 2024
| ATBPF Stock | USD 0.22 0.00 0.00% |
Check Antibe Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Antibe Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Antibe financial statements analysis is a perfect complement when working with Antibe Therapeutics Valuation or Volatility modules.
Antibe |
Antibe Therapeutics Company Shares Owned By Insiders Analysis
Antibe Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Antibe Therapeutics Shares Owned By Insiders | 7.79 % |
Most of Antibe Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Antibe Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 7.79% of Antibe Therapeutics are shares owned by insiders. This is 48.68% lower than that of the Pharmaceuticals sector and 49.9% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 22.79% higher than that of the company.
Antibe Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Antibe Therapeutics's current stock value. Our valuation model uses many indicators to compare Antibe Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Antibe Therapeutics competition to find correlations between indicators driving Antibe Therapeutics's intrinsic value. More Info.Antibe Therapeutics is rated fourth in return on equity category among its peers. It is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Antibe Therapeutics' earnings, one of the primary drivers of an investment's value.About Antibe Therapeutics Financial Statements
Antibe Therapeutics stakeholders use historical fundamental indicators, such as Antibe Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Antibe Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Antibe Therapeutics' assets and liabilities are reflected in the revenues and expenses on Antibe Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Antibe Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada. Antibe Therapeutics is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Antibe Pink Sheet
Antibe Therapeutics financial ratios help investors to determine whether Antibe Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antibe with respect to the benefits of owning Antibe Therapeutics security.